We are live on ! Find out more
PMVP icon

PMV Pharmaceuticals
PMVP

85 hedge funds and large institutions have $1.44B invested in PMV Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 42 increasing their positions, 15 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 15

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

10% more capital invested

Capital invested by funds: $1.31B → $1.44B (+$130M)

5% more funds holding

Funds holding: 81 → 85 (+4)

4.68% more ownership

Funds ownership: 89.14% → 93.82% (+4.7%)

Holders
85
Holders Change
+4
Holders Change %
+4.94%
% of All Funds
1.48%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
16
Increased
42
Reduced
15
Closed
12
Calls
$1.44M
Puts
–
Net Calls
+$1.44M
Net Calls Change
+$1.44M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$35.2M
2
JP Morgan Chase
JP Morgan Chase
New York
+$23.6M
3
BlackRock
BlackRock
New York
+$16.4M
4
DM
Deerfield Management
New York
+$12.7M
5
State Street
State Street
Massachusetts
+$12.5M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$17.9M
2
IVM
InterWest Venture Management
California
-$16.7M
3
PCS
Personal CFO Solutions
New Jersey
-$15.7M
4
Viking Global Investors
Viking Global Investors
Connecticut
-$9.89M
5
EC
Euclidean Capital
New York
-$9.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
26
Federated Hermes
Pennsylvania
$8.54M – – –
OCA
27
Octagon Capital Advisors
New York
$8.54M – – –
WP
28
Woodline Partners
California
$8.17M +$514K +15,391 +7%
Franklin Resources
29
Franklin Resources
California
$7.5M +$655K +19,600 +10%
Invesco
30
Invesco
Georgia
$7.42M -$790K -23,655 -10%
LGM
31
Logos Global Management
California
$7.06M +$219K +6,564 +3%
UBS AM
32
UBS AM
Illinois
$6.55M -$69.8K -2,091 -1%
Assenagon Asset Management
33
Assenagon Asset Management
Luxembourg
$5.62M +$5.49M +164,486 New
Goldman Sachs
34
Goldman Sachs
New York
$5.31M +$2.49M +74,516 +92%
Citadel Advisors
35
Citadel Advisors
Florida
$4.33M +$3.89M +116,602 +1,162%
CC
36
Commodore Capital
New York
$4.27M – – –
Charles Schwab
37
Charles Schwab
California
$3.9M +$975K +29,203 +34%
ACM
38
Asymmetry Capital Management
California
$3.48M -$546K -16,352 -14%
N
39
Nuveen
North Carolina
$3.46M +$1.32M +39,542 +64%
AI
40
Atom Investors
Texas
$3.18M +$3.11M +93,013 New
SFM
41
Sphera Funds Management
Israel
$2.87M +$1.36M +40,718 +94%
Morgan Stanley
42
Morgan Stanley
New York
$2.33M +$1.94M +58,105 +568%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$2.24M +$845K +25,297 +63%
Deutsche Bank
44
Deutsche Bank
Germany
$2.04M +$247K +7,398 +14%
Citigroup
45
Citigroup
New York
$1.83M +$683K +20,459 +62%
Adage Capital Partners
46
Adage Capital Partners
Massachusetts
$1.81M -$835K -25,000 -32%
EC
47
EcoR1 Capital
California
$1.71M – – –
Bank of America
48
Bank of America
North Carolina
$1.37M +$42.5K +1,273 +3%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$1.24M +$518K +15,504 +75%
Rafferty Asset Management
50
Rafferty Asset Management
New York
$1.19M +$275K +8,242 +31%
1
2
3 4

PMVP Hedge Fund Activity: Q2 2021 in Review

85 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q2 2021, worth a combined $1.44B — up 9.9% from $1.31B a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new PMVP positions and 12 closed out — a net gain of 4 holders — while 42 added to existing stakes and 15 trimmed.

The largest buyer was Vanguard Group, adding an estimated $35.2M. The largest seller was Avoro Capital Advisors, cutting an estimated $17.9M.

  • 85 institutional investors held PMV Pharmaceuticals (PMVP) as of Q2 2021, up from 81 in Q1 2021.
  • Funds reported $1.44B of PMV Pharmaceuticals stock for Q2 2021, up 9.9% quarter-over-quarter.
  • 16 funds opened new PMV Pharmaceuticals positions in Q2 2021 and 12 closed out, a net change of +4 holders.
  • The largest PMV Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $35.2M added.
  • The largest PMV Pharmaceuticals seller in Q2 2021 was Avoro Capital Advisors, an estimated $17.9M sold.

Based on aggregated 13F filings for Q2 2021.